Melane Sampson, Author at BioTuesdays

Uncategorized

IceCure reports positive 5-year results from ProSense kidney cancer study

IceCure Medical (NASDAQ: ICCM) has announced positive topline results from the ICESECRET clinical study of its ProSense Cryoablation System for the treatment of small renal masses in kidney cancer patients. Detailed...

March 25, 2026

Developments

Amplia reports more responses and improved OS in pancreatic cancer trial

Amplia Therapeutics (ASX: ATX; OTCQB: INNMF) has announced data from the ongoing ACCENT clinical trial of narmafotinib combined with chemotherapy in advanced pancreatic cancer showing a median overall survival (OS) of...

March 23, 2026

Developments

Bioxytran completes $1.2 million private placement

Bioxytran (OTC: BIXT) has announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million. In connection with the financing, the company issued...

March 20, 2026

Developments

Co-Diagnostics inks agreement to expand distribution across South Asia

Co-Diagnostics (NASDAQ: CODX) has signed an agreement for closely held CoSara Diagnostics—the Indian joint venture between Co-Dx and Ambalal Sarabhai—to significantly expand its commercial and distribution territory...

March 20, 2026

Developments

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Immutep (ASX: IMM; NASDAQ: IMMP) has announced positive Phase 1 results for IMP761, a first-in-class LAG-3 agonist antibody designed to potentially supress pathogenic T cell responses in autoimmune diseases. According...

March 19, 2026

Executive Moves

Evolent names Archie Mayani as CPO

Evolent Health (NYSE: EVH) has announced the appointment of healthcare technology leader and AI innovator, Archie Mayani, as chief product officer (CPO). Ms. Mayani brings more than two decades of leadership experience...

March 19, 2026

Developments

Niagen increases share repurchase program to $20 million

Niagen Bioscience (NASDAQ: NAGE) has announced that its board of directors has authorized an increase to the company’s previously disclosed share repurchase program, raising the total authorization from $10 million to...

March 19, 2026

Developments

Picard / SynCardia’s Total Artificial Heart enables four-year bridge to transplant

Picard Medical (NYSE American: PMI) has announced that a 29-year-old patient successfully received a donor heart transplant after more than four years of being fully supported by the SynCardia Total Artificial...

March 17, 2026

Feature

PolarityBio changing the trajectory of wound care with autologous regenerative biologics

Closely held PolarityBio is developing investigational regenerative biologics for chronic wound healing, targeting some of the most refractory wounds in medicine. The company’s lead program and first entry into the...

March 17, 2026

Developments

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic...

March 16, 2026

Author - Melane Sampson

IceCure reports positive 5-year results from ProSense kidney cancer study

Amplia reports more responses and improved OS in pancreatic cancer trial

Bioxytran completes $1.2 million private placement

Co-Diagnostics inks agreement to expand distribution across South Asia

Immutep reports positive Phase 1 results for IMP761 in autoimmune diseases

Evolent names Archie Mayani as CPO

Niagen increases share repurchase program to $20 million

Picard / SynCardia’s Total Artificial Heart enables four-year bridge to transplant

PolarityBio changing the trajectory of wound care with autologous regenerative biologics

Trial finds Profound’s TULSA Procedure significantly improves erectile function and continence vs. robotic radical prostatectomy

Subscribe